Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Public Health and Preventive Medicine
  4. Vol 5, Issue 2, 2025

Analysis of High-Risk Warning Factors for Severe Mycoplasma Pneumoniae Pneumonia in Children

Download as PDF

DOI: 10.23977/phpm.2025.050205 | Downloads: 8 | Views: 195

Author(s)

Xiao Yijing 1, Deng Huiling 2, Zhang Yufeng 2

Affiliation(s)

1 School of Public Health, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China
2 Infectious Disease, Xi'an Children's Hospital, Xi'an, China

Corresponding Author

Deng Huiling

ABSTRACT

Severe Mycoplasma pneumoniae is a serious respiratory disease caused by Mycoplasma pneumoniae and is characterized by persistent high fever, frequent coughing and shortness of breath. The disease is relatively common in children, and if left untreated, it may rapidly lead to serious complications and even death. In this paper, we systematically summarize the high-risk early warning factors of severe Mycoplasma pneumoniae pneumonia in order to be helpful for the early identification of high-risk factors and the adoption of effective interventions in the clinic.

KEYWORDS

Severe Mycoplasma Pneumoniae Pneumonia, High-Risk Warning Factors

CITE THIS PAPER

Xiao Yijing, Deng Huiling, Zhang Yufeng, Analysis of High-Risk Warning Factors for Severe Mycoplasma Pneumoniae Pneumonia in Children. MEDS Public Health and Preventive Medicine (2025) Vol. 5: 28-33. DOI: http://dx.doi.org/10.23977/phpm.2025.050205.

REFERENCES

[1] Zhao Shunying, Qian Suyun, Chen Zhimin, et al. Guidelines for the diagnosis and treatment of Mycoplasma pneumoniae in children (2023 edition)[J]. Infectious Disease Information, 2023, 36(4): 291-297. 
[2] LIANG Xi, TAN Liqin, WEI Bingmei, et al. Epidemiologic characteristics of Mycoplasma pneumoniae and clinical features of severe Mycoplasma pneumoniae[J]. Systemic Medicine, 2024, 9(4): 100-102.
[3] Wk L, Q L, Dh C, et al. Epidemiology of acute respiratory infections in children in guangzhou: a three-year study [J]. PLoS One, 2014, 9(5).
[4] Pm M S, Ww U, D N, et al. Infection with and carriage of mycoplasma pneumoniae in children[J]. Frontiers in Microbiology, 2016, 7.
[5] Waites K B, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond[J]. Clinical Microbiology Reviews, 2017, 30(3): 747-809.
[6] Ni X. Community-acquired pneumonia diagnosis and treatment standard for children (2019 edition)[J]. Clinical and Education in Family Medicine, 2019, 17(9): 771-777.
[7] Khoury T, Sviri S, Rmeileh A A, et al. Increased rates of intensive care unit admission in patients with mycoplasma pneumoniae: a retrospective study[J]. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2016, 22(8): 711-714.
[8] TANG Fang, YU Jing. Progress in the epidemiology of community-acquired pneumonia pathogens in children[J]. Clinical Medicine Research and Practice, 2022, 7(5): 187-190.
[9] Liu L, Johnson H L, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000[J]. Lancet, 2012, 379(9832): 2151-2161.
[10] Walker C L F, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea[J]. Lancet, 2013, 381(9875): 1405-1416.
[11] Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions-the lancet microbe [EB/OL]. [2025-01-15]. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00344-0/fulltext.
[12] Bajantri B, Venkatram S, Diaz-Fuentes G. Mycoplasma pneumoniae: a potentially severe infection[J]. Journal of Clinical Medicine Research, 2018, 10(7): 535-544.
[13] Xiong Xin, Liu Ling, Zhou Rongrong, et al. Clinical characteristics and misdiagnosis of Mycoplasma pneumoniae in adults with extrapulmonary manifestations[J]. Clinical Misdiagnosis and Mistreatment, 2024, 37(10): 6-10. 
[14] Garcia A V, Fingeret A L, Thirumoorthi A S, et al. Severe mycoplasma pneumoniae infection requiring extracorporeal membrane oxygenation with concomitant ischemic stroke in a child[J]. Pediatric Pulmonology, 2013, 48(1): 98-101.
[15] Thromboembolic complications of Mycoplasma pneumoniae pneumonia in children-PubMed[EB/OL]. [2024-10-31]. https://pubmed.sjuku.top/36658687/.
[16] Xiao Y. Clinical characterization of extrapulmonary manifestations of Mycoplasma pneumoniae in children[D]. Suzhou: Suzhou University, 2023.
[17] ZHOU Fang-Fang, CHEN Ling-Ling, ZHOU Ting-Min. Correlation of extrapulmonary complications of Mycoplasma pneumoniae pneumonia with cytokines and immunoglobulin E in children[J]. China Maternal and Child Health, 2024, 39(15): 2850-2853.
[18] Zhao Shunying, Liu Hanmin, Lu Quan, et al. Expert interpretation of the diagnosis and management of Mycoplasma pneumoniae in children (November 2023)[J]. Chinese Journal of Pediatrics, 2024, 62(2): 108-113.
[19] Gao Hua, Tian Jianmei. Logistic regression analysis of risk factors associated with severe Mycoplasma pneumoniae in children[J]. Journal of Inner Mongolia Medical University, 2023, 45(S1): 130-133.
[20] LIU Liping, YANG Zeyu, WANG Yu, et al. Analysis of clinical characteristics and risk factors associated with severe Mycoplasma pneumoniae pneumonia in children[Z]//Chinese Pediatric Emergency Medicine: vol. 30. 2023: 451-456. 
[21] WANG Yanqiong, DONG Lili, CHEN Chaohui, et al. Expression and significance of peripheral blood cell death-associated factors in children with severe Mycoplasma pneumonia[J]. Journal of Clinical Pulmonology, 2022, 27(7): 1055-1060. 
[22] Liu F, Chen L, Wang M Y, et al. Exploring high-risk factors for the prediction of severe mycoplasma pneumonia in children[J]. Translational Pediatrics, 2024, 13(11): 2003-2011.
[23] CHEN Changxiu, YU Hairong, LI Jian, et al. Analysis of factors affecting severe mycoplasma pneumonia[J]. Journal of Practical Cardiovascular, Cerebral, Pulmonary and Vascular Diseases, 2021, 29(S1): 108-110.
[24] TU Zhirong, LIU Yanchai, LIN Jing, et al. The value of C-reactive protein and D-dimer combined with CT performance in predicting severe mycoplasma pneumonia in pediatric patients[J]. Chinese Journal of Border Health and Quarantine, 2022, 45(1): 71-74.
[25] ZHANG Min. Analysis of clinical characteristics and imaging manifestations of severe Mycoplasma pneumoniae pneumonia in children[J]. Chinese Journal of ct and mri, 2020, 18(2): 37-40.
[26] CHEN Ruifang, ZHOU Xinying, HE Guofang, et al. Clinical value of neutrophil/lymphocyte ratio in evaluating the severity of mycoplasmal pneumonia in children[J]. China Maternal and Child Health, 2022, 37(4): 641-644.
[27] Jia Jia, Jia Chunmei. Predictive value of laboratory indicators for refractory Mycoplasma pneumonia[J]. Inner Mongolia Medical Journal, 2021, 53(12): 1425-1428.
[28] YANG Shuo, LIU Xinying, WANG Huizhe, et al. Meta-analysis of risk factors for severe Mycoplasma pneumoniae in children [J]. Chinese Family Medicine, 2024, 27(14): 1750-1760.
[29] Wang X, Zhong L J, Chen Z M, et al. Necrotizing pneumonia caused by refractory mycoplasma pneumonia pneumonia in children[J]. World Journal of Pediatrics, 2018, 14(4): 344-349.
[30] Wang J, Mao J, Chen G, et al. Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings[J]. Medicine, 2021, 100(3): e23926.
[31] Zhang C, Zhang Q, Du J lin, et al. Correlation between the clinical severity, bacterial load, and inflammatory reaction in children with mycoplasma pneumoniae pneumonia[J]. Current Medical Science, 2020, 40(5): 822-828.
[32] CHEN Mengxue, LI Jingyang, YANG Fen, et al. Clinical characteristics and risk factors of macrolide-resistant severe Mycoplasma pneumoniae in children[J]. Journal of Clinical Pediatrics, 2024, 42(3): 187-192.
[33] Zou Yingxue. Clinical significance of abnormal inflammatory indexes in Mycoplasma pneumoniae[J]. Chinese Journal of Practical Pediatrics, 2021, 36(16): 1209-1214.
[34] Zhang X, Sun R, Jia W, et al. Clinical characteristics of lung consolidation with mycoplasma pneumoniae pneumonia and risk factors for mycoplasma pneumoniae necrotizing pneumonia in children[J]. Infectious Diseases and Therapy, 2024, 13(2): 329-343. 
[35] Fan F, Lv J, Yang Q, et al. Clinical characteristics and serum inflammatory markers of community-acquired mycoplasma pneumonia in children[J]. Clinical Respiratory Journal, 2023, 17(7): 607-617.
[36] He W, Yin J, Wan Y. Correlations of different serological parameters with the severity and prognosis of pneumonia in children infected with mycoplasma pneumoniae[J]. Clinical Laboratory, 2022, 68(12).
[37] YU Yixue, LU Binwang, YANG Minling, et al. Laboratory tests and immunoassay analysis of severe Mycoplasma pneumoniae in children[J]. Jiangsu Medicine, 2024, 50(7): 711-715.
[38] Zhang Y X, Li Y, Wang Y,et al. Prospective cohort study on the clinical significance of interferon-γ, D-dimer, LDH, and CRP tests in children with severe mycoplasma pneumonia[J]. Medicine, 2024, 103(41): e39665.
[39] Qiu J, Ge J, Cao L. D-dimer: the risk factor of children’s severe mycoplasma pneumoniae pneumonia[J]. Frontiers in Pediatrics, 2022, 10: 828437.
[40] Wang Y, Huang L, Qian J, et al. Clinical profile and risk factors for respiratory failure in children with mycoplasma pneumoniae infection[J]. Biomolecules & Biomedicine, 2025.
[41] Paudel R, Dogra P, Montgomery-Yates A A, et al. Procalcitonin: a promising tool or just another overhyped test? [J]. International Journal of Medical Sciences, 2020, 17(3): 332-337.
[42] Weng Cuiqi, Chen Yumei, Jiang Lei, et al. Relationship between serum CRP, PCT and ESR levels and disease severity in pediatric Mycoplasma pneumoniae[J]. Chinese Journal of Hospital Infection, 2022, 32(8): 1220-1223.
[43] QIN Jun, CHEN Ling, DANG Rongrong, et al. Changes in serum vitamin D, CD5L, complement C3, and IgE levels in children with Mycoplasma pneumoniae combined with asthma and their relationship with the disease and the degree of inflammatory response[J]. Chinese Journal of Modern Medicine, 2023, 33(23): 10-15.
[44] Wang Z, Sun J, Liu Y, et al. Impact of atopy on the severity and extrapulmonary manifestations of childhood mycoplasma pneumoniae pneumonia[J]. Journal of Clinical Laboratory Analysis, 2019, 33(5): e22887.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4250
Visits: 239081

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.